Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Liquid Biopsy Assay for the Early Detection of Pancreatic Cancer

By LabMedica International staff writers
Posted on 29 Apr 2020
A liquid biopsy assay for multiple biomarkers enables early detection of pancreatic cancer before it metastasizes and while there are still treatment options available.

The assay, developed by investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA), was designed to detect pancreatic cancer (pancreatic ductal adenocarcinoma or PDAC) while still in its earliest stages. More...


Initially, the investigators analyzed plasma samples from 204 subjects (71 healthy, 44 non-PDAC pancreatic disease, and 89 with PDAC) for the following biomarkers: carbohydrate antigen 19-9 (CA19-9), KRAS mutational burden, tumor-associated extra-cellular vesicle (EV) miRNA, and mRNA isolated on a nanomagnetic platform developed by the investigators. Circulating cell-free DNA (ccfDNA) concentration was measured by qPCR, ccfDNA KRASG12D/V/R mutations were detected by droplet digital PCR, and CA19-9 was measured by ECLIA (enhanced chemiluminescence immunoassay).

Results revealed that in a test group of 47 patients (20 with PDAC, 27 controls), the assay was 92% accurate in its ability to detect PDAC, which was better than measuring the best known PDAC biomarker, CA19-9, alone (89%). In addition, the assay was 84% accurate in determining disease staging in samples from the 25 PDAC patients who imaging showed did not have metastatic disease. This result was significantly better than that obtained by imaging alone (64% accurate).

"Right now, the majority of patients who are diagnosed already have metastatic disease, so there is a critical need for a test that can not only detect the disease earlier but also accurately tell us who might be at a point where we can direct them to a potentially curative treatment," said co-senior author Dr. Erica L. Carpenter, assistant professor of medicine at the University of Pennsylvania School of Medicine. "If validated, this test could not only provide a key tool for at-risk patients, but also a monitoring tool for patients with certain known risk factors like BRCA mutations."

The liquid biopsy assay for detection of pancreatic cancer was described in the April 16, 2020, online edition of the journal Clinical Cancer Research.

Related Links:
University of Pennsylvania School of Medicine


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
Automated PCR System
OnePCR
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.